Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Disorders of Erythrocytes

Disorders of Erythrocytes

Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

Hemodialysis III: Nursing Management

Hemodialysis III: Nursing Management

The nursing management of a patient undergoing hemodialysis includes several critical steps, starting with a thorough assessment before the procedure.Before the Hemodialysis ProcedureFirst, record the patient's vital signs—blood pressure, heart rate, respiratory rate, and temperature—to establish a baseline. This baseline is essential for detecting conditions such as hypotension that could impact the patient's response to dialysis. Document the patient's pre-dialysis weight, as this measurement...

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis.

Blood·2026

Same author

Splenic FDG PET uptake and CT volume as prognostic biomarkers in diffuse large B cell lymphoma.

La Radiologia medica·2026

Same author

Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

Clinical Heterogeneity and Outcome of acquired PRCA: a Multicenter European Study.

Blood advances·2026

Same author

Describing the use of ruxolitinib for the treatment of myelofibrosis: a plain language summary of the ROMEI early study results.

Future oncology (London, England)·2026

Same author

Long term outcomes of idasanutlin therapy in hydroxyurea-refractory polycythemia vera patients.

Leukemia & lymphoma·2026

Search research articles

Related Experiment Video

Updated: May 22, 2026

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

How I treat polycythemia vera.

Francesco Passamonti¹

¹Division of Hematology, Department of Internal Medicine, University Hospital Ospedale di Circolo e Fondazione Macchi, Viale L. Borri 57, Varese, Italy. francesco.passamonti@ospedale.varese.it

|May 22, 2012

Summary

Polycythemia vera (PV) is a blood cancer involving excess red blood cells, often caused by JAK-STAT pathway mutations. Diagnosis, risk stratification for thrombosis, and treatment options like hydroxyurea are key clinical challenges.

Area of Science:

Hematology
Oncology
Molecular Biology

Background:

Polycythemia vera (PV) is a clonal hematopoietic stem cell disorder.
It is characterized by the overproduction of red blood cells.
Mutations in JAK-STAT pathway genes, like JAK2 V617F, are common drivers.

Purpose of the Study:

To discuss challenges in the diagnosis and prognostication of Polycythemia vera.
To review current and emerging therapeutic strategies for PV.
To highlight clinical issues encountered in daily practice.

Main Methods:

Review of diagnostic criteria (WHO, IWG-MRT).
Discussion of risk stratification factors for thrombosis.
Evaluation of current treatment options (hydroxyurea, pegylated IFN-alfa-2a, ruxolitinib).

Related Experiment Videos

Last Updated: May 22, 2026

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

Main Results:

PV diagnosis relies on WHO criteria; post-PV myelofibrosis uses IWG-MRT criteria.
Age >60 and prior thrombosis are primary risk factors for stratification.
Emerging correlations between leukocytosis, JAK2(V617F), BM fibrosis, and outcomes require further study.

Conclusions:

Accurate diagnosis and prognostication are crucial for managing PV.
Hydroxyurea remains a standard cytoreductive therapy.
Newer agents like pegylated IFN-alfa-2a and ruxolitinib show promise in specific settings, pending Phase 3 trial results.